

“Application of the shipment surcharge. The carrier will remit to GSA a shipment surcharge for each shipment equal to that provided in the GSA Request for Offers (RFO) for a specific rate-filing period. The shipment surcharge is due by the end of the quarter in which the carrier bills the agency for line haul and accessorial services, exclusive of storage-in-transit (SIT) charges as provided in paragraph 7-1.A. (9) a., above. The surcharge is not billable to the Federal agency and must be shown on the Original Public Voucher for Transportation Charges, SF 1113, as an allowance to the Government.”

[FR Doc. 99-1204 Filed 1-19-99; 8:45 am]
BILLING CODE 6820-24-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Amended Notice of Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Office of the Secretary, HHS.
ACTION: Notice of meeting.

The Advisory Committee on Blood Safety and Availability will meet on January 28, 1999 from 9 a.m. to 5 p.m. It was previously announced that the Committee would also meet on January 29, 1999. Since it no longer appears that the Committee will require two days to complete its agenda, the meeting is now scheduled to begin at 9 a.m. and conclude at 5 p.m. on January 29, 1999. The meeting will take place in the Crown Plaza Hotel, 14th and K Streets NW, Washington DC 20005. The meeting will be entirely open to the public.

As previously announced, the purpose of the meeting will be to discuss the options for implementation and evaluation of the recommendations made by the Advisory Committee regarding hepatitis C lookback at its November 24, 1998 meeting, and consideration of such Old and New Business as time permits.

Prospective speakers should notify the Executive Secretary of their desire to address the Committee and should plan for no more than 5 minutes of comment.

FOR FURTHER INFORMATION CONTACT: Stephen D. Nightingale, M.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Safety, Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201. Phone (202) 690-5560; FAX (202) 690-6584; e-mail SNIGHTIN@osophs.dhhs.gov.

Dated: January 8, 1999.
Stephen D. Nightingale,
Executive Secretary, Advisory Committee on Blood Safety and Availability.
[FR Doc. 99-1155 Filed 1-19-99; 8:45 am]
BILLING CODE 4160-17-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

President's Committee on Mental Retardation; Notice of Meeting

AGENCY HOLDING THE MEETING: President's Committee on Mental Retardation.

TIME AND DATE: February 20, 1999-11:00 a.m.-5:00 p.m.

PLACE: Renaissance Hotel, 999 9th Street, N.E., Washington, D.C. 20001.

STATUS: Full Committee Meetings are open to the public. An interpreter for the deaf will be available upon advance request. All meeting sites are barrier free.

TO BE CONSIDERED: The Committee plans to discuss critical issues concerning Federal Policy, Federal Research and Demonstration, State Policy Collaboration, Minority and Cultural Diversity and Mission and Public Awareness, relating to individuals with mental retardation.

The PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs, services, and supports for persons with mental retardation. The Committee, by Executive Order, is responsible for evaluating the adequacy of current practices in programs and supports for persons with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families.

CONTACT PERSON FOR MORE INFORMATION: Jane L. Browning, 352-G Hubert H. Humphrey Building, 200 Independence Avenue, S.W., Washington, D.C. 20201-0001, (202) 619-0634.

Dated: January 12, 1999.
Jane L. Browning,
Executive Director, PCMR.
[FR Doc. 99-1203 Filed 1-19-99; 8:45 am]
BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 24, 1999, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Rhonda W. Stover or John Schupp, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss new drug application (NDA) 21-036, zanamivir for inhalation (Relenza®, Glaxo Wellcome, Inc.), for the treatment of influenza A and B.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 17, 1999. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 17, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).